J Fluoresc
particular antibody, was completely prevented from the twist-
ing motion upon irradiation with the excitation light within the
antibody binding site. As a result, no change in fluorescence
intensity of the trans-stilbene molecule was observed, and that
was reported as almost zero fluorescence intensity decay with
time compared to that of the free trans-stilbene molecule
measured in solution [10].
commercially non-applicable. Antibodies, although employed
in many biosensor technologies today, have many essential
drawbacks: 1) limited shelf-lives in the dry or hydrated state,
2) denature in organic solvents and aqueous mixtures, 3)
display background fluorescence signals that lower signal-
to-noise ratios, 4) tend to have bulky molecular volumes
several orders of magnitude larger than the binding ligand of
interest, thereby limiting high density and high intensity fluo-
rescence measurements, 5) frequently fail to produce avid
antibodies to hapten sized analytes such as TNT, and 6) the
cross-reactivity for these small size targets is very high, lead-
ing to a lower specificity. Thus, due to their relatively big size,
it is difficult for antibodies to recognize small molecules with
high sensitivity and selectivity. Besides, antibodies suffer
from batch to batch variation in their structure and function-
ality and denaturation and their generation process involves
the use of animals. As a result, any bioassay or biosensing
system based on the FCIA for detection of a certain analyte
would differ in its sensitivity, and might be difficult to cali-
brate and make generic.
The aforementioned limitations of antibodies can be easily
overcome by replacing them with aptamers, which are single
strand DNA or RNA oligonucleotides. Aptamers are different
from antibodies, yet they mimic properties of antibodies in a
variety of diagnostic formats. They are attracting more and
more attention as a replacement for antibodies due to their
ease of manufacturing, strong affinity and excellent specificity
even for small molecular weight targets. The main advantage
of aptamers is their in-vitro selection process. By isolating
aptamers in-vitro, an aptamer can be produced for any target
molecule. Moreover, aptamers have very long shelf lives, can
be rapidly screened by the SELEX method for new designs,
and can be rapidly scaled for manufacturing. Aptamers are
relatively small in size, can be stabilised in organic/aqueous
solvents, and achieve high ligand-specificity. Therefore, they
are a more logical choice for bioassays than antibodies, in-
cluding the fact that higher surface densities can be placed in a
microtiter plate well-the higher the density, the greater the
sensitivity, especially when combined with metal enhanced
fluorescence. Thus, due to their small size, tuneable stability,
and high ligand-specificity, aptamers seem to be a more log-
ical choice than antibodies in our proposed assay, as it will be
described below.
The majority of commonly employed non-radioactive and
non-enzyme immunoassays are based on physical labelling.
The principle of biophysical labelling approach is based on
chemical modification of chosen sites of the object of interest
by special compounds (labels and probes) whose properties
make it possible to trace the state of the biological matrix by
appropriate physical methods. Several types of physical label-
ling immunoassays have been commonly used at present,
such as Free-Radical Assay Techniques (FRAT); Liposome
Immune Lysis Assay in a combination with FRAT (LILA-
FRAT); Fluorescence Polarisation Immunoassay (FPIA);
Fluorescence Resonance Transfer Immunoassay (FRTIA)
and LILA Fluorescence Immunoassay (LILA-FIA). The gen-
eral advantage of all these modern physical labelling immu-
noassays is monitoring the complex formation between anti-
gens and antibodies in solution without preliminary separa-
tion. Each method has however its limitations. FRAT being
monitored by ESR techniques requires relatively high concen-
tration of the tested compound. Direct luminescence methods,
such as FPIA and FRTIA, appear to be more sensitive but they
require solutions of low optical density and cannot be used in
biological or non-transparent media. FRAT and FPIA are not
practically applicable to antigens of higher molecular weight.
FRTIA requires preliminary labelling of both antigen and
antibody and its limited by a molecular distance critical for
the resonance energy transfer. LILA-FRAT and LILA-FIA,
involve a complicated procedure of liposome preparation and
loading with spin and fluorescent probes, and bearing cova-
lently bound antibodies. The most commonly employed im-
munoassay methods for small antigen molecules appear to be
the FPIA and FRTIA. However, they have two main disad-
vantages: they require special polarisation or resonance instru-
ments, and they are insufficiently sensitive for incident and
emitted light to be polarised. Also, the practical sensitivity of
these methods does not make them commercially viable.
Being a non-separation and rapid immunoassay producing
results within a few minutes and based on time-dependent
fluorescence emission in-situ, the FCIA seems to have a
number of essential advantages over all the above techniques.
Also, the FCIA is a quantitative method and can measure the
concentration of an analyte in a sample by a competitive
binding of the analyte molecules to the active site of the
antibodies occupied by the trans-stilbene-conjugates. Never-
theless, with all its advantages over the listed above tech-
niques, it is still an antibody-based immunoassay with many
disadvantages of using antibodies, which make it
Thus, for the first time, we report here the experimental
studies connected to development of the novel photochrome-
aptamer switch assay (PHASA) allowing state-of-the-art ana-
lyte detection and quantification of small molecules such as
toxins, explosives, drugs and pollutants, which are difficult to
detect using antibodies-based assays with high sensitivity and
specificity, in minutes. In the first stage of the PHASA devel-
opment, we have focused on the so called “adaptive binding”
of the stilbene compound to an aptamer of interest, as it will be
explained in the next section. Synthetic preparation and